Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial

Arman Faravardeh; Sanjeev Akkina; Rafael Villicana; Giselle Guerra; Misbah A. Moten; Ulf Meier-Kriesche; Daniel R. Stevens; Samir J. Patel; Suphamai Bunnapradist

doi:10.12659/AOT.929535

16 April 2021 : Original article

Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial

Arman Faravardeh^1DE*, Sanjeev Akkina^2DE, Rafael Villicana^3DE, Giselle Guerra^4DE, Misbah A. Moten^5ADE, Ulf Meier-Kriesche^5ADE, Daniel R. Stevens^5ACDE, Samir J. Patel^5DE, Suphamai Bunnapradist^6DE

DOI: 10.12659/AOT.929535

Ann Transplant 2021; 26:e929535

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Rates of treatment failure at 12 months.

Outcome	Switched to LCPT	Remained on IR-Tac	P-value*
Outcome	N=26	N=29	P-value*
Composite treatment failure, n (%)	1 (4)	1 (3)	1.0000
Treatment failure due to:
BPAR n (%)	1 (4)	0	0.4727
Death, n (%)	0	0	–
Graft failure, n (%)	0	0	–
Lost to follow up, n (%)	0	1 (3)	1.0000
BPAR – biopsy-proven acute rejection; IR-Tac – immediate-release tacrolimus; LCPT – LCP-tacrolimus. ^* P values were calculated by Fisher’s exact test.

Back to the Article

Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial

Your Privacy